Missing content? – Request curation!
Request curation for specific Genes, variants, or PubMed publications.
Have questions, comments or suggestions? - Let us know!
Email us at : ckbsupport@jax.org
ID | DOID:60061 |
Name | cutaneous T cell lymphoma |
Definition | A non-Hodgkin's lymphoma that has_material_basis_in a mutation of T cells. |
Source | DiseaseOntology.org |
Alt Ids | |
Path | disease disease of cellular proliferation cancer organ system cancer hematologic cancer lymphoma non-Hodgkin lymphoma mature T-cell and NK-cell lymphoma peripheral T-cell lymphoma cutaneous T cell lymphoma |
Molecular Profile | Therapy | Indication/Tumor Type | Response Type | Profile Response Detail |
---|---|---|---|---|
Unknown unknown | Romidepsin | cutaneous T cell lymphoma | not applicable | detail... |
Unknown unknown | Mogamulizumab | cutaneous T cell lymphoma | not applicable | detail... |
Unknown unknown | Duvelisib | cutaneous T cell lymphoma | not applicable | detail... |
Unknown unknown | Lacutamab | cutaneous T cell lymphoma | not applicable | detail... |
Unknown unknown | Tenalisib | cutaneous T cell lymphoma | not applicable | detail... |
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT00671112 | Phase I | Bortezomib + Everolimus | Everolimus and Bortezomib in Treating Patients With Relapsed or Refractory Lymphoma | Terminated | USA | 0 |
NCT01196208 | Expanded access | Brentuximab vedotin | A Treatment-Option Protocol to Provide Brentuximab Vedotin to Eligible Patients Completing Studies SGN35-005 or C25001 | No longer available | USA | 14 |
NCT01637090 | Phase II | Everolimus | Everolimus in Treating Cutaneous T-cell Lymphoma | Terminated | USA | 0 |
NCT01843998 | Phase II | Sirolimus | Therapeutic Efficacy of Topical Sirolimus in Early Stage Cutaneous T-cell Lymphoma (CTCL) | Withdrawn | USA | 0 |
NCT01902225 | Phase I | Pegylated liposomal-doxorubicin + Romidepsin | Phase I Dose-finding and Preliminary Efficacy Study of the Istodax in Combination With Doxil for the Treatment of Adults With Relapsed or Refractory Cutaneous T-cell Lymphoma | Completed | USA | 0 |
NCT01976585 | Phase Ib/II | CDX-301 + Poly ICLC | In Situ Vaccine for Low-Grade Lymphoma: Combination of Intratumoral Flt3L and Poly-ICLC With Low-Dose Radiotherapy | Recruiting | USA | 0 |
NCT02192021 | Phase I | Doxorubicin | Micro Needle Array-Doxorubicin (MNA-D) in Patients With Cutaneous T-cell Lymphoma (CTCL) | Recruiting | USA | 0 |
NCT02512497 | Phase I | Romidepsin Busulfan + Fludarabine + Romidepsin | Romidepsin Maintenance After Allogeneic Stem Cell Transplantation | Recruiting | USA | 0 |
NCT02556463 | Phase I | MEDI9197 Durvalumab + MEDI9197 | A Study of MEDI9197 in Subjects With Solid Tumors or CTCL and in Combination With Durvalumab and Palliative Radiation in Subjects With Solid Tumors | Terminated | USA | CAN | 1 |
NCT02567656 | Phase I | Tenalisib | Safety and Efficacy Study of a Dual PI3K Delta/Gamma Inhibitor in T-cell Lymphoma | Completed | USA | 0 |
NCT02616965 | Phase I | Brentuximab vedotin + Romidepsin | A Study to Assess the Feasibility of Romidepsin Combined With Brentuximab Vedotin in Cutaneous T-cell Lymphoma | Recruiting | USA | 0 |
NCT02643303 | Phase Ib/II | Durvalumab + Poly ICLC Tremelimumab | A Phase 1/2 Study of In Situ Vaccination With Tremelimumab and IV Durvalumab Plus PolyICLC in Subjects With Advanced, Measurable, Biopsy-accessible Cancers | Recruiting | USA | 0 |
NCT02689453 | Phase I | Alemtuzumab + rhIL-15 | Subcutaneous Recombinant Human IL-15 (s.c. rhIL-15) and Alemtuzumab for People With Refractory or Relapsed Chronic and Acute Adult T-cell Leukemia (ATL) | Active, not recruiting | USA | 0 |
NCT02974647 | Phase II | Ruxolitinib | Study of Ruxolitinib in Relapsed or Refractory T or NK Cell Lymphoma | Recruiting | USA | 0 |
NCT02978625 | Phase II | Nivolumab + Talimogene laherparepvec | Talimogene Laherparepvec and Nivolumab in Treating Patients With Refractory Lymphomas or Advanced or Refractory Non-melanoma Skin Cancers | Recruiting | USA | 0 |
NCT03011814 | Phase Ib/II | Durvalumab Durvalumab + Lenalidomide | Durvalumab With or Without Lenalidomide in Treating Patients With Relapsed or Refractory Cutaneous or Peripheral T Cell Lymphoma | Recruiting | USA | 0 |
NCT03017820 | Phase I | VSV-hIFNbeta-NIS | VSV-hIFNbeta-NIS in Treating Patients With Relapsed or Refractory Multiple Myeloma, Acute Myeloid Leukemia, or T-cell Lymphoma | Recruiting | USA | 0 |
NCT03235869 | Phase I | Durvalumab | Radiation Therapy Plus Durvalumab for Tumor-Stage Cutaneous T-Cell Lymphoma | Withdrawn | USA | 0 |
NCT03239392 | Phase Ib/II | BNZ-1 | A Dose-Ranging Study of IV BNZ-1 in LGL Leukemia or Refractory CTCL | Recruiting | USA | 0 |
NCT03240211 | Phase I | Pembrolizumab + Pralatrexate Decitabine + Pembrolizumab + Pralatrexate Decitabine + Pembrolizumab | Study of Pembrolizumab Combined With Decitabine and Pralatrexate in PTCL and CTCL | Recruiting | USA | 2 |
NCT03292406 | Phase II | CD11301 | A Safety, Efficacy and Pharmacokinetics Study of CD11301 for the Treatment of Cutaneous T-Cell Lymphoma (CTCL) (CTCL) | Completed | USA | 2 |
NCT03409432 | Phase II | Brentuximab vedotin + Lenalidomide | Brentuximab Vedotin and Lenalidomide in Treating Patients With Stage IB-IVB Relapsed or Refractory T-Cell Lymphoma | Recruiting | USA | 0 |
NCT03432741 | Phase I | Carfilzomib Daratumumab Obinutuzumab Gemcitabine Trastuzumab Romidepsin Nivolumab Rituximab Belinostat Pembrolizumab | Direct Tumor Microinjection and FDG-PET in Testing Drug Sensitivity in Patients With Relapsed or Refractory Non-Hodgkin Lymphoma, Hodgkin Lymphoma, or Stage IV Breast Cancer | Suspended | USA | 0 |
NCT03601819 | Phase I | Pacritinib | Pacritinib in Relapsed/Refractory Lymphoproliferative Disorders | Terminated | USA | 0 |
NCT03829540 | Phase I | CD4CAR | CD4CAR for CD4+ Leukemia and Lymphoma | Recruiting | USA | 0 |
NCT04136275 | Phase I | Anti-CD37 CAR T cells | CAR-37 T Cells In Hematologic Malignancies | Recruiting | USA | 0 |
NCT04171791 | Phase I | Venetoclax | A Study of ABT-199 (Venetoclax) for Cutaneous T Cell Lymphoma (CTCL) | Recruiting | USA | 0 |
NCT04234048 | Phase I | Fenretinide | Phase 1 Trial of ST-001 nanoFenretinide in Relapsed/Refractory T-cell Non-Hodgkin Lymphoma | Not yet recruiting | USA | 0 |
NCT04423029 | Phase Ib/II | DF6002 + Pembrolizumab DF6002 | Dose Escalation of DF6002 in Patients With Advanced Solid Tumors, and Expansion in Selected Indications | Recruiting | USA | 0 |
NCT04747236 | Phase II | Pralatrexate Belinostat Azacitidine + Romidepsin Gemcitabine Romidepsin | A Randomized, Phase IIB, Multicenter, Trial of Oral Azacytidine Plus Romidepsin Versus Investigator's Choice in Patients With Relapse or Refractory Peripheral T-cell Lymphoma (PTCL) | Not yet recruiting | USA | 0 |